Spotlight Growth
No Result
View All Result
Tuesday, August 16, 2022
  • Login
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
No Result
View All Result
No Result
View All Result
Home Bio/Med/Pharma

BiondVax Pharmaceuticals, Ltd. (NASDAQ: BVXV) Enters into Agreement with Max Planck Society to Develop COVID-19 Nanosized Antibodies

by admin
December 22, 2021
in Bio/Med/Pharma
0
BiondVax Pharmaceuticals NASDAQ BVXV Max Planck Society COVID Antibodies Spotlight Growth

BiondVax Pharmaceuticals NASDAQ BVXV Max Planck Society COVID Antibodies Spotlight Growth

BiondVax Pharmaceuticals, Ltd. (NASDAQ: BVXV) operates as a biopharmaceutical company, which focuses on the research, development, manufacturing, and commercialization of innovative products to treat and prevent infectious diseases. Shares of the biopharma company are soaring 95% through afternoon trading on Wednesday, December 22, 2021. Over the past three months, BiondVax Pharmaceuticals has seen average daily volume of 78,960 shares. However, volume of 130.75 million shares or dollar volume of $370.02 million, has already exchanged hands through late trading Wednesday.

Shares of BiondVax Pharmaceuticals are skyrocketing after the company announced that it has entered into definitive agreements with Max Planck Society (MPG), the parent company of the Max Planck Institute of Biophysical Chemistry and the University Meical Center Gottingen in Germany. The two groups will focus on collaborating on the development and commercialization of innovative COVID-19 nanosized antibodies. The agreement is part of a larger collaboration agreement, which is estimated to be signed in January 2022 and will cover additional infectious diseases.

In in-vitro studies, nanosized antibodies were shown to have superior capabilities of neutralizing the COVID-19 virus and its variants compared to currently-available monoclonal antibody cocktails. The nanosized antibodies hold smaller drug concentrations than existing treatments and can be produced at a lower cost. BiondVax estimates preclinical studies to be completed in 2022 and first in-human clinical trials for 2023.

Mr. Amir Reichman, BiondVax’s CEO, commented, “As Omicron’s recent and rapid emergence makes clear,improved therapeutics are needed to bring COVID-19 under control. The innovative COVID-19 NanoAb candidates offer the potential for a superior therapeutic platform. Overall, the NanoAb platform is an incredible opportunity for BiondVax. It will serve as a basis for an exciting new pipeline of commercially attractive products to address unmet therapeutic needs of diseases such as psoriasis, psoriatic arthritis, asthma, and macular degeneration. The technology is a great fit to our manufacturing site in Jerusalem and our experience and expertise in biological drug development. I wish to thank Professors Görlich and Dobbelstein for their enthusiasm for this project, and Max Planck Innovation’s technology transfer team including Dr. Dieter Link for their assistance in developing this innovative collaboration. BiondVax is in the process of a transformative turnaround, and I am highly confident that these NanoAb therapies present compelling commercial potential and will address important healthcare needs.”

Disclosure: Neither Spotlight Growth nor its officers have any position or relationship with any companies mentioned in this article, but may choose to initiate a position at any time. No payment was made to create this article. This article should not be taken as a solicitation or recommendation to buy or sell any securities. Please conduct your own research and consult your financial advisor to determine your risk tolerance and investment path. We are not licensed brokers or investment advisors.

Tags: BiondVaxbiopharmaceuticalsbiotechBVXVBVXV stockcommon stockCOVID-19COVID19 antibodiesCOVID19 nano sized antibodiesday tradingemerging growthetradeinfectious diseaseinvestinginvesting newsinvestmentMax Planck Societymedicalmicrocap stocksmonoclonal antibodyNASDAQnewspharmaceuticalspublic companyRobinhoodrobinhood armyrobinhood stockssalesservicessmall cap companiessmall cap stockssmall capsSpotlight GrowthSpotlight Growth Stocksstock marketstock market newsstockstradingtreatment
Plugin Install : Widget Tab Post needs JNews - View Counter to be installed
  • Trending
  • Comments
  • Latest
Siyata Mobile NASDAQ SYTA SYTAW SD7 VK7 Purchase Orders Spotlight Growth

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

December 14, 2021
Telcoin TEL Crypto Spotlight Growth

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

June 15, 2021
Decentraland (MANA) is the Proof of Concept for the Emerging Metaverse

Decentraland (MANA) is the Proof of Concept for the Emerging Metaverse

November 22, 2021
Alfi NASDAQ ALF Ridesharing Tablet Rollout Spotlight Growth

Alfi, Inc. (NASDAQ: ALF) Climbs 51% After Entering Into Agreement with Miami-Based Fulfillment & Distribution Center For its Ridesharing Digital Tablet Rollout

June 15, 2021
Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

0
Safe-T SFET NASDAQ UN Presentation

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

0
Safe-T Group SFET Q4 FY 2020 Financial Results

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

0
Safe-T Group NASDAQ SFET FY 2020 Prelim

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

0
OLB Group NASDAQ OLB Q2 2022 Earnings Results Spotlight Growth

OLB Group (NASDAQ: OLB) Continues Record Revenue Growth for 2022

August 15, 2022
Viridian Therapeutics NASDAQ VRDN TED Phase 1 2 Clinical Trial Data Spotlight Growth

Viridian Therapeutics (NASDAQ: VRDN) Shares Positive Clinical Data from Phase 1/2 Trial of VRDN-001 for Treatment of Thyroid Eye Disease

August 15, 2022
Twin Vee PowerCats NASDAQ VEEE Q2 2022 Financial Results Spotlight Growth

Twin Vee PowerCats (NASDAQ: VEEE) Releases Q2 2022 Results Showing 158% Increase in Revenue, Completes Spin-Off of Forza X1 (NASDAQ: FRZA)

August 12, 2022
Is Uber Technologies NYSE UBER Finally Investible Spotlight Growth

Is Uber (NYSE: UBER) Finally Investable?

August 11, 2022

Recent News

OLB Group NASDAQ OLB Q2 2022 Earnings Results Spotlight Growth

OLB Group (NASDAQ: OLB) Continues Record Revenue Growth for 2022

August 15, 2022
Viridian Therapeutics NASDAQ VRDN TED Phase 1 2 Clinical Trial Data Spotlight Growth

Viridian Therapeutics (NASDAQ: VRDN) Shares Positive Clinical Data from Phase 1/2 Trial of VRDN-001 for Treatment of Thyroid Eye Disease

August 15, 2022

Categories

  • Bio/Med/Pharma
  • Cannabis
  • Commodities
  • Consumer Goods
  • Crowdfunding
  • Crypto Cheat Sheets
  • Cryptocurrency
  • Earnings
  • Entertainment
  • Financials
  • Market News
  • Opinion
  • Politics
  • Real Estate
  • Split Watch
  • Sponsored
  • Store
  • Technology
  • Uncategorized
  • Venture Capital/Private Equity (VC/PE)

Site Navigation

  • Disclosures
  • Terms Of Service
  • Privacy Policy
  • Contact Us
Spotlight Growth

Copyright © 2021 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

No Result
View All Result
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener

Copyright © 2021 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Newsletter Signup

Subscribe to our weekly newsletter below and never miss the latest small/micro-cap analysis and investment news from Spotlight Growth.

Enter your email address

Thanks, I’m not interested